80246-70-4

Usage

Uses

Used in Fragrance Industry:
Cycloheptylacetic acid ethyl ester is used as a fragrance ingredient for its fruity and floral scent, contributing to the creation of various perfumes and personal care products.
Used in Flavor Industry:
This ester is also utilized as a flavoring agent in food products, enhancing the taste and aroma profiles of culinary creations.
Used in Pharmaceutical Research:
Cycloheptylacetic acid ethyl ester is being explored for its potential therapeutic properties, particularly in the treatment of neurological disorders, although further research is necessary to confirm its efficacy and safety in this application.

InChI:InChI=1/C11H20O2/c1-2-13-11(12)9-10-7-5-3-4-6-8-10/h10H,2-9H2,1H3

Upstream product

• 124668-83-3 (E)-9-Methanesulfonyloxy-non-2-enoic acid ethyl ester 
• 623-73-4 diazoacetic acid ethyl ester 
• 291-64-5 cycloheptane 
• 502-42-1 cycloheptanone 
• 1903-23-7 ethyl cycloheptylideneacetate 

Downstream Products

• 4480-98-2 2-cycloheptylethanol 
• 146449-40-3 7-Chloro-2-[2-(4-methyl-cyclohexyl)-ethyl]-6-nitro-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one 
• 146449-27-6 7-Hydroxy-2-[2-(4-methyl-cyclohexyl)-ethyl]-6-nitro-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one 
• 118314-10-6 7-Amino-2-[2-(4-methyl-cyclohexyl)-ethyl]-6-nitro-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one 
• 146449-15-2 7-Hydroxy-2-[2-(4-methyl-cyclohexyl)-ethyl]-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one 
• 118313-98-7 5-[2-(4-Methyl-cyclohexyl)-ethyl]-[1,3,4]thiadiazol-2-ylamine 
• 22579-30-2 1-bromo-2-cycloheptylethane 

Relevant academic research and scientific papers

Iron-Catalyzed Intermolecular Functionalization of Non-Activated Aliphatic C?H Bonds via Carbene Transfer

The modification of strong Csp3?H bonds via iron carbene intermediates under mild reaction conditions has been an important challenge with attractive prospective in organic synthesis. In this work, we show the efficient combination of an electrophilic iron catalyst with a lithium Lewis acid for the functionalization of strong Csp3?H bonds of cyclic and linear alkanes by the activation of commercially available ethyl diazoacetate (EDA). The reaction proceeds with good yields, under mild reaction conditions (40 °C) and large excess of substrate is not needed. In addition, excellent activity is observed in the cyclopropanation of challenging aliphatic olefins. (Figure presented.).

1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

The present invention is directed to novel 1,1 -(dimethyl-ethylamino)-2- hydroxy-propoxy]-ethyl}-3-methyl-biphenyl-4-carboxylic acid derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variable R1 is as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS

The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.

Synthesis and antiallergy activity of [1,3,4]thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-one derivatives. II. 6-Alkyl- and 6-cycloalkylalkyl derivatives

A series of 6-alkyl- or 6-(cycloalkylalkyl)-[1,3,4]thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyr imidin-9(3H)-ones 1b-o was synthesized from the corresponding 1,3,4-thiadiazol-5-amines 3b-o and the antiallergic activities of the products were evaluated. Among the compounds 6-(2-cyclohexylethyl)-[1,3,4]thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]p yrimidin-9(3H)-one 1h, whose X-ray crystallographic stereostructure is shown, was found to be a promising new antiallergic agent, which has low toxicity and dual activity as a leukotriene D4 receptor antagonist and as an orally active mast cell stabilizer.

Insights into the Electrochemical Reductive Cyclization of α,β-Unsaturated Carbonyl Derivatives

A series of acyclic and cyclic α,β-unsaturated esters bearing tethered mesylate leaving groups have been electrochemically reduced to give synthetically useful yields of monocyclic and bicyclic esters via attack of the β-carbon of the α,β-unsaturated ester on the carbon bearing the mesylated moiety.